Author: Dino Mustafić

June 14, 2022 Off

ProBiotix Health with new CEO

By Dino Mustafić

ProBiotix Health, a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, has appointed Steen Andersen as Chief Executive Officer.

June 3, 2022 Off

Novartis’ Kisqali the only CDK4/6 inhibitor consistent significant overall survival across entire Phase III program

By Dino Mustafić

Novartis today announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer. These data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,  Novartis said.

April 10, 2022 Off

Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

By Dino Mustafić

Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

April 7, 2022 Off

Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round

By Dino Mustafić

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, has announced the closing of a $10 million funding round led by Kizoo Technology Capital, a early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch.